Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMGN NASDAQ:BIIB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$339.30+0.6%$345.10$267.83▼$391.29$183.12B0.442.82 million shs1.57 million shsBIIBBiogen$193.76+2.3%$185.48$121.05▼$205.97$28.61B0.191.21 million shs892,915 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen0.00%+3.98%-2.67%-9.46%+25.05%BIIBBiogen0.00%+0.42%+3.13%+0.90%+52.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$339.30+0.6%$345.10$267.83▼$391.29$183.12B0.442.82 million shs1.57 million shsBIIBBiogen$193.76+2.3%$185.48$121.05▼$205.97$28.61B0.191.21 million shs892,915 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen0.00%+3.98%-2.67%-9.46%+25.05%BIIBBiogen0.00%+0.42%+3.13%+0.90%+52.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMGNAmgen 2.48Hold$355.194.68% UpsideBIIBBiogen 2.52Moderate Buy$215.6211.28% UpsideCurrent Analyst Ratings BreakdownLatest AMGN and BIIB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026AMGNAmgen ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$400.00 ➝ $375.005/15/2026BIIBBiogen Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$214.00 ➝ $225.005/15/2026BIIBBiogen EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/14/2026BIIBBiogen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/14/2026AMGNAmgen Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$432.00 ➝ $427.005/14/2026BIIBBiogen OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$275.00 ➝ $300.005/13/2026AMGNAmgen Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$410.00 ➝ $390.005/7/2026AMGNAmgen Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/5/2026AMGNAmgen Erste Group BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/4/2026AMGNAmgen GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$351.00 ➝ $340.005/1/2026BIIBBiogen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMGNAmgen$36.75B4.98$33.79 per share10.04$17.03 per share19.92BIIBBiogen$9.89B2.89$22.64 per share8.56$126.33 per share1.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMGNAmgen$7.71B$14.3723.6114.403.4120.96%137.41%13.28%8/4/2026 (Estimated)BIIBBiogen$1.29B$9.3220.7911.701.7113.81%12.83%8.01%7/30/2026 (Estimated)Latest AMGN and BIIB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q1 2026AMGNAmgen$4.77$5.15+$0.38$3.34$8.58 billion$8.62 billion4/29/2026Q1 2026BIIBBiogen$2.95$3.57+$0.62$2.15$2.29 billion$2.48 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMGNAmgen$10.082.97%+8.27%70.15%14 YearsBIIBBiogenN/AN/AN/AN/AN/ALatest AMGN and BIIB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/4/2026AMGNAmgenquarterly$2.523.09%5/15/20265/15/20266/5/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMGNAmgen5.651.261.01BIIBBiogen0.343.062.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMGNAmgen76.50%BIIBBiogen87.93%Insider OwnershipCompanyInsider OwnershipAMGNAmgen0.85%BIIBBiogen0.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMGNAmgen31,500539.68 million535.10 millionOptionableBIIBBiogen7,500147.64 million147.27 millionOptionableAMGN and BIIB HeadlinesRecent News About These CompaniesLSV Asset Management Buys 9,976 Shares of Biogen Inc. $BIIBMay 24 at 5:31 AM | marketbeat.com11,400 Shares in Biogen Inc. $BIIB Purchased by Catalyst Funds Management Pty LtdMay 24 at 4:08 AM | marketbeat.comMarketBeat Week in Review – 05/18 - 05/22 (BIIB)...May 23 at 7:00 AM | marketbeat.comBanque Cantonale Vaudoise Sells 11,683 Shares of Biogen Inc. $BIIBMay 23 at 3:36 AM | marketbeat.comBiogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline RisksMay 22 at 7:39 PM | finance.yahoo.comParkinson’s drug from Biogen, Denali comes up shortMay 22 at 2:39 PM | biopharmadive.comBDenali Stock Dips as Biogen-Partnered Parkinson's Disease Study FailsMay 22 at 2:39 PM | finance.yahoo.comDenali Stock Dips as Biogen-Partnered Parkinson's Disease Study FailsMay 22 at 1:15 PM | zacks.comBiogen Stock Slides After Trial Miss, But Analysts Stay Bullish...May 22 at 12:00 PM | marketbeat.comBiogen, Denali to drop Parkinson’s therapy after mid-stage trial setbackMay 22 at 9:39 AM | seekingalpha.comBiogen Inc. (BIIB) Securities Fraud Investigation - Levi & KorsinskyMay 22 at 9:00 AM | prnewswire.comDenali, Biogen Halt Parkinson’s Trial After Efficacy FailureMay 22 at 6:51 AM | tipranks.comBIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In TrialMay 21 at 11:31 PM | stocktwits.comSINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIBMay 21 at 6:40 PM | prnewswire.comBiogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s DiseaseMay 21 at 6:30 PM | finance.yahoo.comBiogen, Denali scrap Parkinson's drug after failure in mid-to-late stage studyMay 21 at 6:17 PM | reuters.comBiogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinsonâs DiseaseMay 21 at 6:11 PM | markets.businessinsider.comBiogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's DiseaseMay 21 at 6:00 PM | globenewswire.comAre Wall Street Analysts Bullish on Biogen Stock?May 20, 2026 | finance.yahoo.comLevi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB)May 20, 2026 | globenewswire.comBIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities FraudMay 19, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026Biogen Stock Slides After Trial Miss, But Analysts Stay BullishBy Chris Markoch | May 22, 2026AMGN and BIIB Company DescriptionsAmgen NASDAQ:AMGN$339.30 +1.88 (+0.56%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$340.28 +0.98 (+0.29%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.Biogen NASDAQ:BIIB$193.76 +4.29 (+2.26%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$193.50 -0.26 (-0.13%) As of 05/22/2026 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
